What is NextCure, Inc.'s market cap?

NextCure, Inc. (NXTC) has a market capitalization of $20.8M and trades on NASDAQ.

Who are NextCure, Inc.'s competitors?

NextCure, Inc.'s key competitors include Nuvectis Pharma, Inc. Common Stock, CNS Pharmaceuticals, Inc. Common Stock, NeOnc Technologies Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does NextCure, Inc. partner with?

NextCure, Inc.'s notable partners include Simcere Zaiming Pharmaceutical Co., Ltd., LigaChem Biosciences, Inc., Yale University, and others.

Where is NextCure, Inc. headquartered?

NextCure, Inc. is headquartered in United States of America and employs approximately 82 people. It has been publicly traded since 2019.

NextCure, Inc.

NXTC

NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies for patients who are non-responsive to current treatments.

Market cap

$20.83M+55.4%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$1.87Miss by $0.06

Read the full report

Next report

Aug 6, 2026 (In 1 week)

EPS estimate-$1.98

Competitors

By market cap

Nuvectis Pharma, Inc.$616.0M+288%

NTH

Neonc Technologies Holdings, Inc.$89.2M-13.3%

Cardiff Oncology$65.0M-73.8%

CTO

Citius Oncology, Inc.$51.7M-64.7%

Lantern Pharma$35.6M-17.7%

NXT

NextCure, Inc.$20.8M+40.5%

Citius Pharmaceuticals$14.2M-17.6%

CNS Pharmaceuticals$7.4M-83.4%

Profile

NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies for patients who are non-responsive to current treatments. The company specializes in antibody-drug conjugates (ADCs) that target specific biological pathways and biomarkers within the tumor microenvironment. Its core value proposition lies in leveraging proprietary payloads and linkers to enhance the therapeutic window and safety profile of targeted oncology medicines.

Competitive position

A clinical-stage developer of next-generation ADCs utilizing unique binding epitopes and proprietary payloads to differentiate from established oncology therapies.

GeographiesUnited States, Global

Customer segmentsPharmaceutical Companies, Patients

Business modelR&D focused, Licensing and Royalties, Collaborative Development

SuppliersContract manufacturing organizations, Specialized chemical linker suppliers, Academic research institutions, Clinical trial site operators

CustomersGlobal pharmaceutical companies, Specialty oncology clinics, Hospitals

CountryUnited States of America

Listed2019

Employees82.0

CEOMichael S. Richman

SectorHealthcare

IndustryBiotechnology

Websitenextcure.com

FilingsSEC EDGAR

Questions, answered.

What is NextCure, Inc.'s market cap?: NextCure, Inc. (NXTC) has a market capitalization of $20.8M and trades on NASDAQ.
Who are NextCure, Inc.'s competitors?: NextCure, Inc.'s key competitors include Nuvectis Pharma, Inc. Common Stock, CNS Pharmaceuticals, Inc. Common Stock, NeOnc Technologies Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does NextCure, Inc. partner with?: NextCure, Inc.'s notable partners include Simcere Zaiming Pharmaceutical Co., Ltd., LigaChem Biosciences, Inc., Yale University, and others.
Where is NextCure, Inc. headquartered?: NextCure, Inc. is headquartered in United States of America and employs approximately 82 people. It has been publicly traded since 2019.